Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Human immunodeficiency virus 1 | Aberrant vpr protein | Starlite/ChEMBL | No references |
Homo sapiens | APEX nuclease (multifunctional DNA repair enzyme) 1 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | tar DNA binding protein | 0.007 | 1 | 1 |
Schistosoma mansoni | ap endonuclease | 0.0023 | 0.1842 | 0.1842 |
Loa Loa (eye worm) | DNA ligase | 0.0025 | 0.228 | 0.228 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.007 | 1 | 1 |
Schistosoma mansoni | ap endonuclease | 0.0023 | 0.1842 | 0.1842 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0023 | 0.1842 | 0.1842 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0023 | 0.1842 | 0.5 |
Brugia malayi | DNA ligase | 0.0025 | 0.228 | 0.228 |
Trypanosoma cruzi | DNA ligase I, putative | 0.0025 | 0.228 | 1 |
Trichomonas vaginalis | DNA ligase IV, putative | 0.0025 | 0.228 | 1 |
Schistosoma mansoni | DNA ligase I | 0.0025 | 0.228 | 0.228 |
Trypanosoma brucei | DNA ligase I, putative | 0.0025 | 0.228 | 1 |
Onchocerca volvulus | DNA ligase 3 homolog | 0.0012 | 0 | 0.5 |
Giardia lamblia | DNA ligase | 0.0025 | 0.228 | 1 |
Mycobacterium ulcerans | ATP-dependent DNA ligase | 0.0025 | 0.228 | 1 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0023 | 0.1842 | 0.1842 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.0023 | 0.1842 | 0.1842 |
Schistosoma mansoni | tar DNA-binding protein | 0.007 | 1 | 1 |
Plasmodium falciparum | DNA ligase I | 0.0025 | 0.228 | 1 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0023 | 0.1842 | 0.5 |
Loa Loa (eye worm) | TAR-binding protein | 0.007 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.007 | 1 | 1 |
Leishmania major | DNA ligase I, putative | 0.0025 | 0.228 | 1 |
Trypanosoma cruzi | DNA ligase I, putative | 0.0025 | 0.228 | 1 |
Schistosoma mansoni | DNA ligase I | 0.0025 | 0.228 | 0.228 |
Brugia malayi | TAR-binding protein | 0.007 | 1 | 1 |
Plasmodium vivax | DNA ligase I, putative | 0.0025 | 0.228 | 1 |
Toxoplasma gondii | DNA ligase 1, putative | 0.0025 | 0.228 | 1 |
Loa Loa (eye worm) | RNA binding protein | 0.007 | 1 | 1 |
Entamoeba histolytica | DNA ligase, putative | 0.0025 | 0.228 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.007 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.007 | 1 | 1 |
Echinococcus multilocularis | tar DNA binding protein | 0.007 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.007 | 1 | 1 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0023 | 0.1842 | 0.1842 |
Brugia malayi | RNA recognition motif domain containing protein | 0.007 | 1 | 1 |
Toxoplasma gondii | exonuclease III APE | 0.0023 | 0.1842 | 0.8079 |
Echinococcus granulosus | DNA ligase 1 | 0.0025 | 0.228 | 0.228 |
Echinococcus multilocularis | DNA ligase 1 | 0.0025 | 0.228 | 0.228 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0023 | 0.1842 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 3.9811 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the HIV-1 protein Vpr. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.